Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Sodium fluorescein→

Fluorescein Sodium PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
518-47-8
PubChem CID
10608
Molecular formula
C20H10Na2O5
Molecular weight
376.3 g/mol

Identification source: PubChem record (CID 10608). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Fluorescent diagnostic dye; ophthalmic and angiographic imaging agent

Mechanism of action

Fluorescein absorbs blue light and emits green-yellow fluorescence. It is used as a tracer to visualise ocular-surface defects or, after intravenous administration, retinal and choroidal vascular circulation; sodium is a counter-ion and does not change the fluorescein chromophore.

General use cases

  • Diagnostic fluorescein angiography of the retina and choroid following intravenous administration
  • Ocular-surface staining to identify corneal epithelial defects and assess tear-film integrity when used in topical ophthalmic preparations
Active moiety: fluorescein (Simple salt/counter-ion form; shares the same API pharmacology and general use cases.)

Fluorescein is the diagnostic dye moiety; sodium is the counter-ion. Use depends on route and product (e.g. intravenous retinal angiography versus topical ocular staining).

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Fluorescein Sodium PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Fluorescein Sodium Permitted Daily Exposure (PDE) report (the Fluorescein Sodium PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Fluorescein Sodium Occupational Exposure Limit (OEL) report (the Fluorescein Sodium OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.